Huang Xiaojun

[Expert Profile] Huang Xiaojun, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in hematology and hematopoietic stem cell transplantation in China, working at the Institute of Hematology, Peking University People's Hospital. He has long been dedicated to the clinical diagnosis, treatment, and scientific research of paroxysmal nocturnal hemoglobinuria, leukemia, and hematopoietic stem cell transplantation, and is an internationally renowned hematologist.

[Education & Career] Professor Huang Xiaojun graduated from Beijing Medical University (now Peking University Health Science Center), completed systematic clinical training at Peking University People's Hospital, and further studied at famous international hematology centers. He has long served as Director of the Institute of Hematology at Peking University People's Hospital, holding important academic positions including Chair of the Hematology Branch of the Chinese Medical Association. He has presided over major projects including the National Key R&D Program, and is a representative leader in the fields of hematology and hematopoietic stem cell transplantation both domestically and internationally.

[Areas of Expertise] Professor Huang specializes in the diagnosis and treatment of various leukemias, myelodysplastic syndromes, and difficult hematological diseases, with profound expertise particularly in hematopoietic stem cell transplantation. His "Beijing Protocol" — a haploidentical (half-matched) hematopoietic stem cell transplantation system — successfully solved the worldwide problem of donor shortage, enabling nearly all patients in need of transplantation to find a donor. He is proficient in core techniques including conditioning regimen design, graft-versus-host disease (GVHD) prevention and treatment, and post-transplant relapse management, helping countless hematological disease patients gain a new lease on life.

[Academic Achievements & Industry Contributions] The "Beijing Protocol" haploidentical transplantation technology system created by Professor Huang has been widely recognized by the international hematology community and incorporated into multiple international guidelines, known as "the Chinese solution to the dilemma of hematopoietic stem cell donor shortage," making China rank first in the world in terms of haploidentical transplantation volume. He has led the establishment of a nationwide hematology diagnosis and treatment and transplantation collaboration network, and has presided over multiple international multi-center clinical trials, with research findings published in top international journals including the New England Journal of Medicine. He has received multiple national awards including the National Science and Technology Progress Award, and is a meritorious figure driving the development of hematopoietic stem cell transplantation not only in China but globally.

[Clinical Practice & Outstanding Contributions] For decades on the front lines of hematology and transplantation clinical work, Professor Huang has led his team in completing tens of thousands of hematopoietic stem cell transplants, with transplant success rates and long-term survival rates ranking at the international leading level, bringing new hope to countless leukemia patients and their families. He has been invited to deliver keynote reports at international academic conferences on multiple occasions, and is a flagship figure representing Chinese hematology on the international stage. With noble medical ethics and a spirit of nurturing talent, he has trained a large number of core professionals in hematology and transplantation, and is deeply loved by patients and admired by peers alike.

[Honors & Reputation] Professor Huang Xiaojun serves as Director of the National Clinical Research Center for Hematologic Diseases and Director of Peking University Institute of Hematology, among other academic positions. He has presided over national-level major projects including the National Key R&D Program, and is an authoritative expert in the field of hematopoietic stem cell transplantation in China. He pioneered the "Beijing Protocol" haploidentical hematopoietic stem cell transplantation system, solving the worldwide problem of donor shortage and making "everyone has a transplant donor" a reality. His findings have been published in top international journals and received the National Science and Technology Progress Award (Second Class), and are widely recognized and promoted by the international bone marrow transplantation community. Leading his team, he has completed tens of thousands of various transplant procedures, trained a large number of hematology and transplantation professionals, and is deeply trusted by patients and respected by peers alike. He is a leading figure in the field of hematology in China.